Overview

Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During Treatment of Chronic Plaque Psoriasis

Status:
Completed
Trial end date:
2004-11-01
Target enrollment:
Participant gender:
Summary
An extension study to evaluate safety and tolerability of up to 3 additional courses of IM alefacept in patients with chronic plaque psoriasis who have been previously treated with 1 or 2 courses of IM alefacept.
Phase:
Phase 3
Details
Lead Sponsor:
Astellas Pharma Inc
Collaborator:
Biogen
Treatments:
Alefacept